Search clinical trials for: plaque psoriasis

Total 15006 results

Escalier Biosciences B.V.
Innovaderm Research Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis

Psoriatic Plaque

United States, Canada
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-R)

Plaque Psoriasis

United States, Puerto Rico, Canada
Alvotech Swiss AG

Completed

Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Poland, Georgia, Estonia, Ukraine
NKGen Biotech, Inc.

Completed

Autologous Natural Killer Cells in Subjects With Plaque Psoriasis

Plaque Psoriasis

Mexico
Pfizer

Completed

Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis

Psoriasis

Germany
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Puerto Rico, United States, Germany, Poland, Japan, Canada
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S)

Plaque Psoriasis

Germany, Spain, Belgium, France, Hungary, Austria, Canada, Italy, Netherlands, Poland, Sweden, Switzerland, United Kingdom
Eli Lilly and Company

Completed

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (IXORA-P)

Plaque Psoriasis

Argentina, Puerto Rico, United States, Australia, Taiwan, Japan, Hungary, Korea, Republic of, Mexico, Germany, Poland, Romania, Czechia, Canada
AbbVie (prior sponsor, Abbott)

Completed

Documentation of Humira in Psoriasis Patients in Routine Clinical Practice (LOTOS)

Moderate to Severe Plaque Psoriasis

Germany
AbbVie

Completed

Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea (ped PsO rPMS)

Psoriasis

Korea, Republic of
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Japan
Amgen

Completed

Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast

Plaque Psoriasis

United States
Amgen

Completed

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp (STYLE)

Psoriasis

United States, Canada
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

Psoriasis

United States, Canada
Amgen

Completed

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

Psoriasis-Type Psoriasis | Plaque-Type Psoriasis

United States
Amgen

Completed

A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Canada, Spain, United States, Germany
Amgen

Completed

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

Psoriasis | Plaque-type Psoriasis

United States, Canada
Amgen

Completed

Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis

Psoriasis | Psoriatic Arthritis | Psoriasis Arthropatica

Japan
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects

Moderate to Severe Plaque Psoriasis

China
Amgen

Completed

Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis (PSOR-003)

Psoriasis

Canada, Czechia, Germany
Amgen

Completed

Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis (PSOR-001)

Psoriasis

United States
AbbVie

Completed

A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece (CONCORDIA)

Moderate to Severe Plaque Psoriasis

Greece
Psoriasis Treatment Center of Central New Jersey
Sun Pharmaceutical Industries Limited

Unknown

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Psoriasis

United States
Coherus Biosciences, Inc.

Completed

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PsOsim)

Plaque Psoriasis

United States, Canada, Bulgaria, Chile, Croatia, Estonia, Georgia, Israel, Italy, Latvia, Moldova, Republic of, Poland, Russian Federation, Slovakia, South Africa, Ukraine
Pfizer

Completed

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
PRCL Research Inc.

Completed

A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis | Psoriasis Vulgaris

Canada, Slovakia, Ukraine
Universita di Verona
Azienda Ospedaliera Universitaria Integrata Verona

Unknown

Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy

Coronavirus Infection
Fresenius Kabi SwissBioSim GmbH
PRA Health Sciences

Completed

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Rheumatoid Arthritis | Plaque Psoriasis | Crohn Disease | Ulcerative Colitis | Hidradenitis Suppurativa | Psoriatic Arthritis | Non-infectious Uveitis | Ankylosing Spondylitis | Pediatric Crohns Disease | Polyarticular Juvenile Idiopathic Arthritis | Pediatric Plaque Psoriasis

United States
Jiangsu HengRui Medicine Co., Ltd.

Suspended

A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults

Plaque Psoriasis

China
Janssen-Cilag G.m.b.H

Completed

A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (POLARIS)

Psoriasis

Germany
Therapeutics, Inc.

Completed

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (305)

Plaque Psoriasis

United States
LEO Pharma

Completed

A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

Psoriasis Vulgaris

Germany
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Plaque Psoriasis

United States
Association Francaise pour la Recherche Thermale
University Hospital, Grenoble; Floralis

Completed

Evaluation of Spa Therapy in the Treatment of Plaque Psoriasis

Plaque Psoriasis

France
Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Bausch Health Americas, Inc.

Terminated

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)

Psoriasis

United States, Germany, Poland, Switzerland, France, Canada
Bausch Health Americas, Inc.

Terminated

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

Plaque Psoriasis

United States, Belgium, Italy, Hungary, Poland, Australia, France, Greece, Russian Federation, Latvia, Canada
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Plaque Psoriasis

China, Thailand, Philippines, Turkey, Hungary, Malaysia
Universität Duisburg-Essen
Poomulli Neelakandan Namboodiripad Memorial Ayurveda Medical College

Unknown

Ayurvedic Treatment Package in Plaque Psoriasis

Psoriasis

India
LEO Pharma

Completed

Efficacy and Tolerability of Enstilar® in Daily Practice

Plaque Psoriasis

Germany
Janssen Research & Development, LLC
Innovaderm Research Inc.

Completed

Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products

Psoriasis Vulgaris

France
AbbVie (prior sponsor, Abbott)
Cato Research; JSS Medical Research Inc.

Completed

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis (Complete-PS)

Psoriasis

Canada
Akeso
Akeso Tiancheng, Inc

Completed

A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Celgene

Terminated

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

Healthy Volunteers | Parapsoriasis

United States
AbbVie
Boehringer Ingelheim

Completed

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
UCB Biopharma S.P.R.L.

Completed

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-1)

Psoriasis | Plaque Psoriasis

United States, Canada, Czechia, Germany, Hungary

3

Subscribe